Stakeholder Summit

Research shows that addiction is a chronic disease similar to diabetes and hypertension, with long-term treatment success equal to or better than those diseases.

"No state legislature would put a time limit on medications for any other chronic disease, such as diabetes or hypertension," said ASAM President Stuart Gitlow, MD. "Yet there is a patchwork of such policies across the country on addiction medications."

On June 20, 2013, the Advancing Access to Addiction Medications Stakeholder Summit convened invited guests to examine the Patient Advocacy Task Force's survey and research results. Participants reviewed the research results; considered the responses of federal, state, and insurance industry leaders; and discussed how the organizations represented could collaborate going forward to promote patient access to these life-saving medications. Click here to read the full Summit Report.


 

Michael Botticelli, Deputy Director of the Office of National Drug Control Policy, speaks at the Advancing Access to Addiction Medications Press Conference.


See photos from the Advancing Access to Addiction Medications Stakeholder Summit and Press Conference here.



 

Final Agenda

 

8:00 am                           Registration and Continental Breakfast

 

8:30-10:00 am                  Welcome: Stuart Gitlow, MD, MPH, MBA, FAPA, President, ASAM

                                       Opening Remarks: The Honorable Paul D. Tonko, U.S. Representative, 20thDistrict New York

                                       Public and Private Payer Benefit Survey Results: Suzanne Gelber, PhD, Avisa Group and Mady Chalk, PhD, Treatment Research Institute

                                       Treatment and Clinical Cost Effectiveness Research Results: Tom McLellan, PhD, Treatment Research Institute

10:00-10:30 am                Audience Q & A

10:30-11:30 am                Press Conference

                                       Speakers: Stuart Gitlow, MD, MPH, MBA, FAPA, President, ASAM;  Tom McLellan, PhD, CEO and co-founder, Treatment Research Institute; Whitney, a patient taking buprenorphine

11:30 am-1:00 pm         Panel: Federal, State, and Private Payer Response and Audience Q&A

Speakers:

  • Michael Botticelli, Deputy Director, Office of National Drug Control Policy 
  • Barbara A. Cimaglio, Deputy Commissioner, Alcohol and Drug Programs, Vermont Department of Health
  • H. Westley Clark, MD, JD, MPH, CAS, FASAM, Director, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Servies Administration
  • Andrea Kopstein, PhD, MPH, Director, Division of Services Improvement, Centers for Substance Abuse Treatment, Substance Abuse and Mental Health Servies Administration
  • Douglas Nemecek, MD, Board Member, Association of Behavioral Health and Wellness
  • John O'Brien, MA, Senior Policy Advisor, Centers for Medicare and Medicaid Services
  • Mark Stringer, MA Director, Missouri Division of Behavioral Health
  • Jack Stein, PhD, Director, Office of Science Policy and Communications, National Institute on Drug Abuse 

1:00-2:00 pm                  Working Lunch

The Task Force will facilitate discussions about the research results and how stakeholder groups can collaborate on efforts to expand patient access to addiction medications.

2:00-3:00 pm                    Reports from Lunch Groups

Each table will have an opportunity to share their feedback and ideas with the full group and to field questions from summit participants.

3:00 pm                              Closing Remarks: Stuart Gitlow, MD, MPH, MBA, FAPA, President, ASAM

View the attendee roster here.